Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of Vraylar (cariprazine) in the Treatment of Bipolar Depression

Article Link: Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of Vraylar (cariprazine) in the Treatment of Bipolar Depression

DUBLIN and BUDAPEST, Hungary, May 28, 2019 /PRNewswire/ — Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Vraylar…

Source: FDA New Drug Approvals